Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

Sanofi SNY announced an agreement with ImmuNext Inc for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis 160 Sanofi s share price has gained 2 5 in the past one year compared with Zacks classified Large Cap